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Abstract
Background/Aim. Although radiotherapy is considered to
be a standard treatment of stage A testicular seminoma, an
increasing number of studies have reported encouraging re-
sults of the treatment by carboplatin monochemotherapy
(CBDCA). The aim of this study was to analyse the treat-
ment results of patients with clinical stage A seminoma
treated by CBDCA on daily basis in the period June 1999 to
September 2008. Methods. A total of 124 patients, mean
age 36.63 years (20–62 years), with stage A testicular semi-
noma were treated, upon radical orchiectomy, by adjuvant
CBDCA (400 mg/m2 on day 1 and 22). Results. Chemo-
therapy was well tolerated, except moderate nausea on the
day of the drug administration and the following day. No
patient had any serious disorders in blood cells count re-
quiring substitutional treatment. During the mean follow-up
period of  37.5 (range 6–111) months, three relapses were
noted (2.41%) and none neoplasm of contralateral testicle
or any other organ. Conclusion. Simple and easy carbo-
platin administration with excellent treatment results, along
with good tolerance and absence of comorbidity, poses it-
self as a new “gold standard” of treatment for stage A tes-
ticular seminoma.
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Apstrakt
Uvod/Cilj. Iako se radioterapija smatra standardom u lečenju
seminomskih tumora testisa u stadijumu A, u literaturi se po-
javljuje sve veći broj studija koji iznose ohrabrujuće rezulate
lečenja primenom monohemioterapije karboplatinom
(CBDCA). Cilj ove studije bila je analiza rezultata lečenja se-
minomskih tumora testisa u kliničkom stadijumu A tretiranih
monohemioterapijom karboplatinom u periodu od juna 1999.
do septembra. 2008. godine. Metode. Ukupno 124  bolesnika,
prosečne starosti 36,63 godine (20–62 godine) sa seminom-
skim tumorom testisa u kliničkom stadijumu A lečeno je na-
kon radikalne orhiektomije adjuvantnom monohemioterapi-
jom karboplatinom. Karboplatin je primenjen u dozi 400
mg/m2 telesne površine u kratkotrajnoj infuziji 1. i 22. dana.
Rezultati.   Hemioterapija je podneta veoma dobro izuzev
blage mučnine koja se javljala na dan terapije i sledećeg dana.
Nijedan bolesnik nije imao ozbiljnijih problema sa krvnom sli-
kom koji bi zahtevali primenu supstitucione terapije. Tokom
prosečnog perioda praćenja od 37,5 meseci (raspon 6–111 me-
seci) javila su se tri recidiva bolesti (2,41%), ali nije došlo do
pojave neoplazme na drugom testisu ili na drugim organima.
Zaključak. Jednostavna i laka primena karboplatina sa odlič-
nim rezultatima lečenja, uz dobru toleranciju od strane boles-
nika i odsustvo komorbiditeta, nameće se kao novi „zlatni sta-
ndard“ u lečenju seminomskih tumora testisa u stadijumu A.
Ključne reči:
testis, neoplazme; lečenje lekovima; karboplatin;
orhiektomija; prognoza.
Introduction
Standard treatment of clinical stage A testicular semi-
noma includes radical orchiectomy and adjuvant radiother-
apy of ipsilateral pelvic and paraaortic lymph nodes. This
treatment has been applied in the past 50 years, and yielded
excellent results with low recurrence rate (2–5%), and ex-
cellent tumor-specific survival (over 98%) 
1, 2. However, ra-
diotherapy has its disadvantages. First of all, the duration of
therapy itself and stress accompanying it, as well as deterio-
ration of quality of life during its application. In addition,
during follow-up period, the appearance of  secondary ma-
lignancies was recorded, also, gastrointestinal tract disorders
(peptic ulcer) and contralateral testicle tumor 
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tive to radiotherapy was surveillance, resulting in a rather
high relapse rate (15–25%), increased morbidity, related to
additional cisplatin chemotherapy followed by nephrotoxic-
ity, ototoxicity, neurotoxicity and marked nausea and vom-
iting 
4–7, 10.
Given that seminomas are chemo- and radiosensitive, a
new option has emerged – carboplatin 
7. Carboplatin is  less
toxic cisplatin analogue, which appeared to be effective for
the treatment of advanced seminomas. Carboplatin mono-
therapy proved to be highly efficient for eradication of mi-
crometastatic disease. The results of recently published
studies proved almost hundred percent of effectiveness, and
in comparison with other therapies, this mode of treatment
posed itself as the most effective 
11–14. However, it has to be
taken into account that all the published results have been
based on studies with relatively short follow-up period. Nev-
ertheless, the latest results are promising.
We presented the treatment results of patients with
stage A testicular seminoma treated with two cycles of car-
boplatin and the mean follow-up period of 37.5  (range 6–
111) months.
Methods
The patients with clinical stage A, histologically veri-
fied pT1, pT2 and pT3 testicular seminoma, and negative re-
section margins following the radical orchiectomy were in-
cluded in the study. Clinical stage was determined according
to physical examination, blood cells count and serum bio-
chemical analysis, tumor markers (AFP, βhCG) levels before
surgical intervention and on 7th postoperative day. Also, ul-
trasonography of the testicles and abdomen, computerized
tomography (CT) of  the abdomen and pelvis and chest radi-
ography were performed. All the patients had normal AFP
values (elevated AFP values excluded the patients from the
study). Seventeen patients had elevated βhCG, normalizing
following radical orchiectomy. A total of 124 patients with
clinical stage A testicular seminoma were treated in the pe-
riod June 1999 – September 2008. Approximately two weeks
after the orchidectomy, on an outpatient basis, carboplatin
was administered iv in the dose of 400 mg/m
2 with hydration
before and after the infusion in a total period of 150 minutes,
along with antiemetics (ondansetron 2 × 8 mg). Chemother-
apy was given in two cycles every 21st day. Complete blood
cells count analysis was performed every 7 days.
During the first year of follow-up, monthly determi-
nation of tumor markers (AFP, βhCG) and ultrasound of
the abdomen and contralateral testicle were performed,
while chest radiography was performed in three-month in-
tervals. Computerized tomography of the abdomen and
pelvis was done once per year. In the second year, the ex-
aminations were performed in a two-month intervals (tu-
mor markers, ultrasound, chest radiography every 6
months); in year 3, the patients were examined on a 4-
month basis (tumor markers, ultrasound, chest radiography
every 6 months). After that the control exams were per-
formed every 6 months until the fifth year. Until now, all
the patients presented with normal findings.
Results
In the period June 1999 to September 2008, 124 pa-
tients were treated for clinical stage A seminoma of testicles.
Mean age of the patients was 36.65 years, the youngest being
20 and the oldest 62 years. Out of them, 29 patients were
younger than 30 years of age and 95 patients were over 30
years (Table 1).
Table 1
Age distributions of the treated patients
Age (years) Patients (n)
20–24 07
25–29 022
30–34 027
35–39 023
40–44 020
45–49 012
≥ 50 013
Total 124
The left testicular tumor was found in 57 patients
(45.96%), while tumor of the right testicle was recorded in
67 patients (54.04%). There were 25 cases with histological
stage pT1, 79 with pT2 and 20 patients with pT3.
All 124 patients were treated with two cycles of carbo-
platin chemotherapy. All the patients had normal AFP values
before and after the orchiectomy and 17 patients had ele-
vated βhCG normalizing following radical orchiectomy. The
therapy was well tolerated by all the patients except for mild
nausea (16%) and vomiting (6%) (WHO grade 1). Along
with the therapy, an antiemetic (ondansetron 2 × 8 mg) was
administered. The therapy with the antiemetic continued for
the next two post-treatment days.
Leukocytopenia grade 1 was reported in seven patients,
while thrombocytopenia was noted in two of them. There
were no episodes of febrile neutropenia. No delayed therapy
for any reason was needed in any of these patients.
Three recurrences (2.41%) were reported in the mean
follow-up period of 37.5 months (range 6–108). The first, 4
months after the therapy only with elevation of βhCG to 360,
the second, 12 months after the therapy with relapse in the
retroperitoneal lymph nodes (stage B3) and elevation of
βhCG to 68, and the third, 30 months after the therapy with
relapse in the retroperitoneal lymph nodes (stage B3). These
three patients were treated with 4 cycles of PE protocol (cis-
platin and etoposide) and complete remission was obtained.
They were in the follow-up period for 20, 24 and 10 months,
respectively. Fifty-six patients were followed-up for three or
more years, amog them 23 patients for more than five years
(Table 2).
Out of 124 patients, 72 fathered children before the on-
set of treatment, 43 patients were single, six patients pre-
sented to andrologic clinic for the impaired sperm count pa-
rameters and infertility, and five fathered children after the
therapy was completed (12 months after the completion in all
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Table 2
Follow-up period of the treated patients
Months Patients (n)
≥   60 23
≥   48 14
≥   36 19
≥   24 22
≥   12 32
≤   12 14
Total 124
Discussion
Testicular tumors are among the most curable neoplasms.
Seminomas account for almost half of all testicular tumors, out
of which ¾ are in clinical stage A. A total cure of testicular
seminomas is achieved in over 95% 
22. Until cisplatin and car-
boplatin were introduced in the therapy, a standard treatment
of stage A testicular seminomas was radical orchiectomy and
adjuvant radiotherapy, without any controversies. However,
perennial follow-up of patients treated by conventional radio-
therapy revealed late side effects, first of all, to gastrointestinal
system, as well as development of secondary malignancy in a
high proportion of patients 
3. Some authors, in search for solu-
tion, reduce radiation dose or narrow radiation field with satis-
factory effect 
1. On the other hand, it is apparent that radio-
therapy itself is over treatment for some patients, with poten-
tially unnecessary late effect of radiation.
Due to above-mentioned facts, a new treatment option
has arisen that will be equally successful with less toxic ef-
fects and less impact on patients daily activities. Surveillance
as one of treatment options after radical orchiectomy was a
good choice regarding the reduction of complications and
side effects of radiotherapy. However, the consequence was
high percentage of recurrence (even 33% as reported by
some studies) 
19, 23, 24. In the follow-up period of testicular
seminomas, tumor markers (AFP, βhCG) are highly unreli-
able 
20. Relapse of tumors are usually detected by imaging
techniques (ultrasound, CT), requiring regular control exams.
Although the recurrence is successfully treated by combined
cisplatin chemotherapy followed by high complete cure rate,
toxicity of therapy and the need for retroperitoneal lymph-
adenectomy increase the morbidity and mortality.
Oliver et al. 
8 first published the treatment results of
clinical stage A testicular seminoma, by adjuvant monoche-
motherapy with two carboplatin cycles. After 16-month fol-
low-up, one recurrence was reported. Dieckmann et al. 
12 re-
ported, in their study of 82 patients who had received 2 car-
boplatin cycles, no recurrence after monitoring of 16 months,
as well as Krege et al. 
13 who followed 43 patients 28
months. Nost et al. 
11 monitored 36 patients during 52
months and reported no recurrence. In two largest published
series, Reiter et al. 
20 reported no recurrence in 107 patients
followed-up approximately 74 months after the administra-
tion of 2 carboplatin cycles, and Steiner et al. 
16 described
two recurrences among 108 patients during mean follow-up
period of 59.8 months. Dieckman et al. 
14, comparing the ef-
fectiveness of one and two carboplatin cycles, noted that
there were no recurrence in the group of 32 patients that re-
ceived 2 cycles, while there was 8.6% of recurrence in the
group of 93 patients that had only one cycle (average follow-
up period of 48 months). Aparicio et al. 
21 reported 2 recur-
rences in 60 patients treated by two Carboplatin cycles dur-
ing follow-up of 52 months. In their latest series, Oliver et al. 
2
treated 560 patients with one carboplatin cycle, and they re-
ported 4.8% of recurring diseases during a 48-month follow-
up period, that was almost equal (5.2%) to series of 885 pa-
tients treated with radiotherapy.
We analyzed 124 patients cured by 2 cycles of carbo-
platin (400 mg/m
2, on the 1st and 21st day). In the mean
follow-up period of 37.5 (range 6–111) months, only three
recurrences were recorded (2.41%), confirming the effec-
tiveness of two carboplatin cycles for clinical stage A tes-
ticular seminoma.
Toxicity profile was presented in mild nausea and
vomiting, as well as leukocytopenia. Drug concentration in a
dose of 400 mg/m
2 was sufficient and did not require to be
increased or corrected, according to AUC curve allowing ap-
plication of a higher drug dose. The drug administration in-
terval every 21 days was associated with no side effects that
would require delay of therapy which was comparable with
the observation of  other authors 
16, 20.
Out of 19 married patients without children before the
therapy, seven had no problem having a baby 12 months af-
ter the completition of the therapy, while six have presented
to andrologic clinic for treatment of the impaired sperm
count parameters (mild oligoasthenospermia).
Conclusion
Reviewing the literature data and our experience with
administration of two carboplatin cycles as adjuvant mono-
chemotherapy in patients with clinical stage A testicular
seminoma, we believe that two cycles in a dose of 400
mg/m
2 administered every 21 days are an excellent treatment
option. The effectiveness of the therapy, absence of signifi-
cant toxic effects as well as good tolerance of therapy are the
major qualities of a such treatment option. The necessity of
long-term follow-up of these patients is significant for
evaluation of probable late toxic effects of treatment, al-
though, if any, they are expected to be minimal, affecting the
fertility of patients and overall survival.
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